Anti-Müllerian hormone predicts benefit of chemo + endocrine therapy in under-55s with breast cancer

Дата публикации: 12-08-2026 21:00:02

Anti-Müllerian hormone (AMH) appears to predict the benefit of chemotherapy plus endocrine therapy (CET) versus ET alone in premenopausal women younger than 55 years with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with a recurrence score (RS) ≤25, according to a study published online July 24 in the Annals of Oncology.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Regional differences in chemotherapy treatment for breast cancer may affect survival, Swedish study finds	0	6.96	13-08-2026
2	Leveraging Artificial Intelligence (AI) Based Algorithm for Accurate Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis in Breast Cancer Diagnostics: Potential to be a Crucial Aid in Routine Workflow [version 2; peer review: 2 approved]	0	8.44	03-08-2026
3	Rb's unexpected activation of estrogen-responsive genes could explain breast cancer treatment resistance	0	8.64	13-08-2026
4	Breast screening misses 95 per cent of young women who go on to develop cancer, study suggests	0	6.75	04-08-2026
5	New insights into early-onset breast cancer ‘reassuring’	0	10.98	23-07-2026
6	MamoRisk project to validate in Spain a new breast cancer risk prediction model	0	9.77	20-07-2026
7	Breast cancers can recruit bone cells to increase tumor growth	0	8.49	14-08-2026
8	Ученые: заместительная гормонотерапия увеличивает риск развития рака молочной железы	0	0	30-08-2019
9	Повышена эффективность комбинированной химиотерапии рака груди	0	0	13-05-2025

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 12.26. Источник: medicalxpress.com.